Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:atccode |
L02 AE01
|
| gptkbp:brand |
gptkb:Eligard
|
| gptkbp:class |
gptkb:Hirogen
|
| gptkbp:clinical_trial |
improves survival rates
compared to other treatments evaluated for safety and efficacy shown to reduce tumor size studied in phase III trials |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to leuprolide |
| gptkbp:dosage_form |
22.5 mg
|
| gptkbp:effective_date |
FDA approved
|
| gptkbp:formulation |
injectable suspension
|
| gptkbp:frequency |
every 3 months
|
| https://www.w3.org/2000/01/rdf-schema#label |
Eligard 22.5 mg
|
| gptkbp:indication |
advanced prostate cancer
|
| gptkbp:ingredients |
gptkb:leuprolide_acetate
|
| gptkbp:interacts_with |
anticoagulants
antidiabetic medications other hormone therapies |
| gptkbp:is_monitored_by |
bone density
hormone levels blood glucose levels |
| gptkbp:manufacturer |
gptkb:Taro_Pharmaceuticals
|
| gptkbp:name |
included in WHO essential medicines list
|
| gptkbp:ndc |
00074-1234
|
| gptkbp:packaging |
single-dose vial
|
| gptkbp:patient_education |
avoid pregnancy during treatment
report severe side effects store in the refrigerator do not shake the vial follow-up appointments are necessary |
| gptkbp:pharmacokinetics |
excreted in urine
metabolized in the liver subcutaneous absorption reduces testosterone levels |
| gptkbp:previous_name |
gptkb:leuprolide_acetate
|
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:shelf_life |
24 months after manufacturing
|
| gptkbp:side_effect |
fatigue
nausea weight gain injection site reactions hot flashes |
| gptkbp:storage |
refrigerate
|
| gptkbp:used_for |
gptkb:Oncology
|
| gptkbp:bfsParent |
gptkb:Eligard
|
| gptkbp:bfsLayer |
6
|